I have yet to find what reaction and or results occur with men that are Stage 4 PCA that Received Lu-177 Pluvicto and had Germline or Genectic Mutations.
Any Research on this to compel treatment?
I have yet to find what reaction and or results occur with men that are Stage 4 PCA that Received Lu-177 Pluvicto and had Germline or Genectic Mutations.
Any Research on this to compel treatment?
May be here some informations
onclive.com/view/garje-eluc...
Thank you
Below paragraph doesn’t state whether men are being separated by
Brca 1 or 2, Germline or Genectic Mutations
With lutetium Lu 177 vipivotide tetraxetan being established as a SOC in mCRPC, what’s next for this agent’s investigation, and what do we still need to know about its use?
Currently, lutetium Lu 177 vipivotide tetraxetan (Pluvicto; formerly 177Lu-PSMA-617) is approved in later lines of therapy in metastatic prostate cancer after patients have been treated with ARPIs and chemotherapy. There are 2 different directions the field is [headed in. One is] trying to move this drug into earlier lines prior to chemotherapy. [The phase 3] PSMAfore trial [NCT04689828] looked into this, and it showed significant PFS benefit [with earlier use of the radioligand] when compared with an ARPI switch. At the same time, [the agent] has also been evaluated in the first-line setting in metastatic castration-sensitive prostate cancer. [This includes the] recent PSMAddition trial [NCT04720157,] which has just finished enrollment; we are waiting [to see the] results. These [kinds of] drugs are now moving earlier in the lines.
There are also studies looking at combining [radioligands] with various agents. Lutetium Lu 177 vipivotide tetraxetan has been combined with immunotherapy drugs, PARP inhibitors, chemotherapy, and also radiation therapy to try and enhance efficacy. As we saw inthe phase 3 VISION study [NCT03511664], patients benefit from lutetium Lu 177 vipivotide tetraxetan, but the responses are not durable. We’re trying to identify patients who are benefiting [from the agent] and make [responses] more durable by using different combination strategies.
Tall_Allen any information on results or reactions with men with pca and mutations?
I think you are misconstruing the genetic tests. I would presume all PCA have genetic mutations, otherwise it wouldn't be cancer. Some mutations are more deleterious than others. As long as the cancer is PSMA advid, the Pluvicto should work,
I’m seeking information on any men whom survived Lu-177 treatment and have mutations
I think you are asking the wrong question. As @MoonRocket says, Lu-177 works on PSMA-avid cancer. I have several mutations and I got nearly two years of undetectable PSA after five treatments.
I read your question as a fairly simple one: if you've had Lu-177 therapy, what gene mutations do you have and how did you handle the treatment.
My Foundation One report says:
Biomarker Findings : Microsatellite status: MS-Stable; Tumor Mutational Burden: 0 Muts/Mb
Genomic Findings: MYC amplification; STAT3 Y640F subclonal
14 Disease relevant genes with no reportable alterations: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD518, RAD51C, RAD51D, RAD54L
I tolerated the treatment (on steroid protocol) with minor SEs: nausea (very well controlled by medication) and dry mouth (drinking lots of water to this day).
Hope this is the information you're looking for.
I have tested positive for BRCA 1 gene and had LU1-77. Cancer had spread extensively. Think it saved my life(for now). Three treatments out of the country because I had not had the previous ADT, Chemo required here. Was still hormone sensitive and it was very effective in reducing PSA. As with Miccoman, dry mouth and drank lots of water.